Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-30
2009-10-27
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S370000
Reexamination Certificate
active
07608625
ABSTRACT:
The present invention provides a preventive or therapeutic agent for bruxism or bruxism-related diseases that contains as an active ingredient at least one selected from the group consisting of proton pump inhibitors, histamine H2receptor antagonists, and acid pump antagonists. Examples of the proton pump inhibitors include rabeprazole, omeprazole, esomeprazole, lansoprazole, pantoprazole, or tenatoprazole, or salts thereof, or hydrates thereof.
REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4758579 (1988-07-01), Kohl et al.
patent: 4808596 (1989-02-01), Matsuishi et al.
patent: 5045552 (1991-09-01), Souda et al.
patent: 5840910 (1998-11-01), Souda et al.
patent: 5916904 (1999-06-01), Sato et al.
patent: 5948789 (1999-09-01), Larsson et al.
patent: 5998445 (1999-12-01), Souda et al.
patent: 6063782 (2000-05-01), Kimura et al.
patent: 6426369 (2002-07-01), Sato et al.
patent: 6740667 (2004-05-01), Sato et al.
patent: WO 94/28923 (1994-12-01), None
patent: WO 01/62290 (2001-08-01), None
Bartlett et al., Drugs of Today (1998), 34(3): 231-239.
Cross et al., Annals of Pharmacotherapy, (May, 2002) 36(5), pp. 912-916.
Chase et al., Mental Health Aspects of Developmental Disabilities, (2002), 5(2), pp. 34-45.
Rogers et al., Am. J. Ment. Retardation, (Mar. 1992), 96(5):522-7 (abstract).
Shaw et al., ASDC J. Dent. Child., 65(6), (Nov.-Dec. 1998), pp. 484-486.
Bell et al., Aust. Dent. J., 47(1), (Mar. 2002), pp. 30-35.
Abstract of Katayama, A., et al., “Effect of Gastric-Acid-Inhibiting Drugs on Rhythmic Masticatory Muscle Activity,” presented at the 82ndGeneral Session and Exhibition of the IADR, accessible online at http://iadr.confex.com/iadr/2004Hawaii/techprogram/abstract—44719.htm on Nov. 27, 2003.
Lavigne G.J., Manzini, C., “Bruxism” In: Kryger MH, Roth T, Dement WC, editors.Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders, 2000, 773-785.
Lobbezoo, F., et al., “The Effect of the Catecholamine Precursor L-Dopa on Sleep Bruxism: A Controlled Clinical Trial,”Movement Disorders12:73-78, Movement Disorder Society (1997).
Miyawaki, S., et al., “Association Between Nocturnal Bruxism and Gastroesophageal Reflux,”Sleep26:888-892, Associated Professional Sleep Societies, LLC (Nov. 2003).
Patent Abstracts of Japan, English language abstract for JP 01-290628 A, (1989).
Patent Abstracts of Japan, English language abstract for JP 02-022225 A, (1990).
The Merck Manual, 17thEdition, Merck Research Laboratories, Chapter 20, pp. 232-233 (1999).
Miyawaki, S., et al., “Association between nocturnal bruxism and gastroesophageal reflux,” presented at 81stGeneral Session of the IADR, Sweden, 4 pages (Jun. 27, 2003).
Abstract published inJ. Dent. Res.82:B-296, Abstract No. 2284, International and American Associations for Dental Research (Jun. 2003; published online Feb. 25, 2003).
Becht, J.L. and T.D. Byars, “Gastroduodenal ulceration in foals,” Equine Vet J., 18: 307-12, Equine Veterinary Journal Ltd, Cambs, UK, (July 1986).
Cuypers, J. et al., “Therapy of cluster headache with histamine H1 and H2 receptor antagonists,” Eur Neurol: 18: 345-7, S. Karger AG, Basel (Jan. 1979).
Dieckmann, M. And E. Deegen, “Magenulzera beim Pferd—klinische und gastroskopische Befunde bei 12 Pferden (1989-1990)” [“Stomach ulcers in the horse—clinical and gastroscopic findings in 12 horses (1989-1990) ”],Tierarztl Prax: 19(4): 386-394, Schattauer, (Aug. 1991).
E.L. Spierings, “Headache of gastrointestinal origin: case studies,” Headache: 42(3): 217-9, Wiley InterScience (Mar. 2002).
K. Taniyama, from Chapter 9 of “New Pharmacodynamics revised fourth edition,” C. Tanaka and R. Kato., eds., Nankodo Co., Ltd., Tokyo, Japan, publishers, pp. 452-454 (2002).
Partial English translation of document NPL16: K. Taniyama, from Chapter 9 of “New Pharmacodynamics revised fourth edition,” C. Tanaka and R. Kato., eds., Nankodo Co., Ltd., Tokyo, Japan, publishers, pp. 452-454 (2002).
Miyawaki Shouichi
Yamamoto Teruko
Clark Sara E
Eisai R & D Management Co. Ltd.
Krass Frederick
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Method for treating bruxism and bruxism-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating bruxism and bruxism-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating bruxism and bruxism-related diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070206